Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2016 1
2017 1
2018 4
2019 1
2021 1
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance.
Tait JR, Harper M, Cortés-Lara S, Rogers KE, López-Causapé C, Smallman TR, Lang Y, Lee WL, Zhou J, Bulitta JB, Nation RL, Boyce JD, Oliver A, Landersdorfer CB. Tait JR, et al. Among authors: rogers ke. Antimicrob Agents Chemother. 2023 Aug 17;67(8):e0041423. doi: 10.1128/aac.00414-23. Epub 2023 Jul 10. Antimicrob Agents Chemother. 2023. PMID: 37428034 Free PMC article.
Ceftolozane/tazobactam plus tobramycin against free-floating and biofilm bacteria of hypermutable Pseudomonas aeruginosa epidemic strains: Resistance mechanisms and synergistic activity.
Agyeman AA, López-Causapé C, Rogers KE, Lucas DD, Cortés-Lara S, Gomis-Font MA, Fraile-Ribot P, Figuerola J, Lang Y, Franklyn ERT, Lee WL, Zhou J, Zhang Y, Bulitta JB, Boyce JD, Nation RL, Oliver A, Landersdorfer CB. Agyeman AA, et al. Among authors: rogers ke. Int J Antimicrob Agents. 2023 Sep;62(3):106887. doi: 10.1016/j.ijantimicag.2023.106887. Epub 2023 Jun 12. Int J Antimicrob Agents. 2023. PMID: 37315906
Penicillin G concentrations required for prophylaxis against Group A Streptococcus infection evaluated using a hollow fibre model and mathematical modelling.
Tait JR, Barnett TC, Rogers KE, Lee WL, Page-Sharp M, Manning L, Boyd BJ, Carapetis JR, Nation RL, Landersdorfer CB. Tait JR, et al. Among authors: rogers ke. J Antimicrob Chemother. 2022 Jun 29;77(7):1923-1930. doi: 10.1093/jac/dkac124. J Antimicrob Chemother. 2022. PMID: 35470370 Free PMC article.
Evaluation of Meropenem-Ciprofloxacin Combination Dosage Regimens for the Pharmacokinetics of Critically Ill Patients With Augmented Renal Clearance.
Agyeman AA, Rogers KE, Tait JR, Bergen PJ, Kirkpatrick CM, Wallis SC, Bulitta JB, Paterson DL, Lipman J, Nation RL, Roberts JA, Landersdorfer CB. Agyeman AA, et al. Among authors: rogers ke. Clin Pharmacol Ther. 2021 Apr;109(4):1104-1115. doi: 10.1002/cpt.2191. Epub 2021 Mar 12. Clin Pharmacol Ther. 2021. PMID: 33550617
Effect of Different Piperacillin-Tazobactam Dosage Regimens on Synergy of the Combination with Tobramycin against Pseudomonas aeruginosa for the Pharmacokinetics of Critically Ill Patients in a Dynamic Infection Model.
Tait JR, Bilal H, Rogers KE, Lang Y, Kim TH, Zhou J, Wallis SC, Bulitta JB, Kirkpatrick CMJ, Paterson DL, Lipman J, Bergen PJ, Roberts JA, Nation RL, Landersdorfer CB. Tait JR, et al. Among authors: rogers ke. Antibiotics (Basel). 2022 Jan 13;11(1):101. doi: 10.3390/antibiotics11010101. Antibiotics (Basel). 2022. PMID: 35052977 Free PMC article.
Combating Carbapenem-Resistant Acinetobacter baumannii by an Optimized Imipenem-plus-Tobramycin Dosage Regimen: Prospective Validation via Hollow-Fiber Infection and Mathematical Modeling.
Landersdorfer CB, Yadav R, Rogers KE, Kim TH, Shin BS, Boyce JD, Nation RL, Bulitta JB. Landersdorfer CB, et al. Among authors: rogers ke. Antimicrob Agents Chemother. 2018 Mar 27;62(4):e02053-17. doi: 10.1128/AAC.02053-17. Print 2018 Apr. Antimicrob Agents Chemother. 2018. PMID: 29339388 Free PMC article.
Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients.
Rees VE, Yadav R, Rogers KE, Bulitta JB, Wirth V, Oliver A, Boyce JD, Peleg AY, Nation RL, Landersdorfer CB. Rees VE, et al. Among authors: rogers ke. Antimicrob Agents Chemother. 2018 Oct 24;62(11):e01150-18. doi: 10.1128/AAC.01150-18. Print 2018 Nov. Antimicrob Agents Chemother. 2018. PMID: 30104278 Free PMC article.
Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model.
Landersdorfer CB, Rees VE, Yadav R, Rogers KE, Kim TH, Bergen PJ, Cheah SE, Boyce JD, Peleg AY, Oliver A, Shin BS, Nation RL, Bulitta JB. Landersdorfer CB, et al. Among authors: rogers ke. Antimicrob Agents Chemother. 2018 Mar 27;62(4):e02055-17. doi: 10.1128/AAC.02055-17. Print 2018 Apr. Antimicrob Agents Chemother. 2018. PMID: 29437610 Free PMC article.
Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling.
Yadav R, Rogers KE, Bergen PJ, Bulitta JB, Kirkpatrick CMJ, Wallis SC, Paterson DL, Nation RL, Lipman J, Roberts JA, Landersdorfer CB. Yadav R, et al. Among authors: rogers ke. Antimicrob Agents Chemother. 2018 Apr 26;62(5):e00078-18. doi: 10.1128/AAC.00078-18. Print 2018 May. Antimicrob Agents Chemother. 2018. PMID: 29463528 Free PMC article.
14 results